Cyclophosphamide ni dawa yenye ufanisi inayotumika kutibu saratani na baadhi ya magonjwa ya mfumo wa kinga, lakini inaweza kuharibu seli za uzazi zinazogawanyika kwa kasi. Inaweza kupunguza idadi na uhamaji wa mbegu kwa kusababisha DNA damage, oxidative stress, mitochondrial dysfunction, kupotea kwa germ cells na hormonal imbalance ndani ya testis.

Utafiti huu uliangalia kama crude polysaccharide fraction iitwayo CP-1, iliyopatikana kutoka kwa malighafi ya mimea Polygonati Rhizoma iliyosindikwa kwa black bean, inaweza kupunguza sperm motility impairment iliyosababishwa na cyclophosphamide.

Male C57BL/6J mice wenye umri wa wiki nane walitumika. Kwa siku tano wanyama walipewa kwa intraperitoneal:

\[ 50\ \mathrm{mg/kg/gün\ siklofosfamid} \]

. Baadaye, kwa siku 30 mice walipokea:

• maji pekee,
• 20 mg/kg/gün CP-1,
• 100 mg/kg/gün CP-1, au
• 2 mg/kg/gün clomiphene citrate.

Kila kundi lilikuwa na mice watano tu.

Katika cyclophosphamide-treated mice, sperm concentration, total motility, progressive motility na proportion ya sperm zinazosonga mbele kwa haraka zilipungua kwa kiasi kikubwa. CP-1 ilileta partial recovery katika vipimo vyote hivi. Kwenye grafu, 100 mg/kg CP-1 inaonekana kuwa effective zaidi kuliko 20 mg/kg katika sperm motility measures nyingi.

Progressive motility rate, yaani PR percentage, ni moja ya vipimo vya msingi vya asthenozoospermia katika utafiti. Kwa maelezo inaweza kuandikwa:

\[ \mathrm{PR\%} = \frac{\mathrm{ileri\ yönde\ hareket\ eden\ sperm\ sayısı}} {\mathrm{toplam\ değerlendirilen\ sperm\ sayısı}} \times 100 \]

Utafiti ulifafanua asthenozoospermia kama:

\[ \mathrm{PR} < 32\% \]

. PR ya cyclophosphamide group ilikuwa chini ya kiwango hiki, huku motility ikiongezeka kwa kiasi kikubwa hasa katika high-dose CP-1 group. Hata hivyo, utafiti ulipima mouse sperm; hakuna human semen analysis iliyofanywa.

Katika sections za testis, baada ya cyclophosphamide kulionekana kuvurugika kwa seminiferous tubule structure, germ cells kuwa disorganized, spaces kutokea na kupungua kwa sperm cells ndani ya tubule lumen. Baada ya CP-1, tubule structure, germ-cell layers na Johnsen spermatogenesis score ziliboreka kiasi.

Watafiti walifanya single-cell RNA sequencing ili kuchunguza kwa kina cellular changes ndani ya testis. Kabla ya quality control kulikuwa na cells 87.496 na baada ya filtering cells 78.277 zilibaki kwenye analysis:

• Sham group: cells 20.988
• Cyclophosphamide group: cells 27.658
• CP-1 group: cells 29.631

Major cell populations tisa zilitambuliwa:

• Spermatogonia
• Spermatocytes
• Spermatids
• Leydig cells
• Sertoli cells
• Endothelial cells
• Fibroblasts
• Macrophages
• T cells

Katika cyclophosphamide group, transition ya spermatocytes kwenda spermatids iliripotiwa kuvurugika, spermatid proportion ikapungua na spermatocytes zikajikusanya kwa kiasi. CP-1 iliongeza spermatid proportion na kusogeza cellular distribution kiasi kuelekea healthy group.

Pseudotime analysis ilijenga kwa computational namna germ-cell development trajectory ilivyo:

\[ \mathrm{Spermatogonyum} \rightarrow \mathrm{Spermatosit} \rightarrow \mathrm{Spermatid} \]

. Katika CP-1 group, late-stage spermatids zilirejea kwa kiasi. Pseudotime si real-time cell tracking; ni statistical developmental ordering inayotokana na gene-expression similarities.

Single-cell analysis iliangazia genes nyingi zinazohusiana na sperm movement, spermatogenesis, spermatid development na flagellar structure. Zikiwemo:

• Prm1 na Prm2,
• Tnp1 na Tnp2,
• Smcp,
• Odf2,
• Catsperz na Catsper4,
• Tekt3,
• Dnaaf11,
• Crisp2.

zinapatikana.

Mechanism kuu ya molekuli iliyopendekezwa ni uhusiano kati ya miR-27b na CRISP2:

\[ \mathrm{Siklofosfamid/PM} \rightarrow \mathrm{miR\!-\!27b}\uparrow \rightarrow \mathrm{CRISP2}\downarrow \rightarrow \mathrm{sperm\ hareketliliği}\downarrow \]

\[ \mathrm{CP\!-\!1} \rightarrow \mathrm{miR\!-\!27b}\downarrow \rightarrow \mathrm{CRISP2}\uparrow \rightarrow \mathrm{sperm\ hareketliliğiyle\ ilişkili\ programlar}\uparrow \]

Katika mouse testis na GC-2spd(ts) mouse spermatocyte cells, phosphoramide mustard, active metabolite ya cyclophosphamide, iliongeza miR-27b na kupunguza CRISP2 expression. CP-1 ilibadilisha kwa kiasi mabadiliko haya.

miR-27b mimic ilipotolewa kwa cells, CRISP2 mRNA na protein levels zilipungua; miR-27b inhibitor au CP-1 ilirudisha CRISP2 juu. Hii inaunga mkono kwamba CP-1 inaweza kupunguza miR-27b-mediated suppression ya CRISP2.

Hata hivyo, hakuna new luciferase reporter assay iliyofanywa kuthibitisha direct binding ya miR-27b kwenye target site ya Crisp2 mRNA. Direct targeting imetegemezwa na previous literature na current mimic/inhibitor results.

CP-1 pia ilibadilisha markers zinazohusiana na oxidative stress na inflammation. Katika cyclophosphamide group:

• malondialdehyde — MDA iliongezeka,
• superoxide dismutase — SOD activity ilipungua,
• ROS gene-set activity iliongezeka,
• TNF-α, IL-1β na IL-6 ziliongezeka.

Kwa CP-1, MDA ilipungua, SOD activity na Prdx6b expression ziliongezeka; TNF-α, IL-1β na IL-6 zilipungua katika cell culture.

Katika serum hormones, cyclophosphamide ilipunguza testosterone na inhibin B huku FSH na LH zikiongezeka. CP-1, hasa high dose, iliongeza testosterone na inhibin B na kupunguza kwa kiasi ongezeko la FSH na LH.

Findings hizi zinaonyesha kwamba CP-1 inaweza kufanya kazi si kwa pathway moja tu, bali kwa pamoja kwenye germ-cell differentiation, sperm-motility-related genes, oxidative stress, inflammation na hormonal balance.

Hata hivyo, utafiti hauonyeshi kwamba CP-1 inatibu infertility kwa binadamu. Mating success, pregnancy rate, number of offspring, offspring health na human semen outcomes havikutathminiwa. CP-1 si molecule moja safi ya kikemia, bali ni heterogeneous crude polysaccharide mixture yenye molecular weights katika range pana.

Tatizo kuu la utafiti ni lipi?

Lengo la chemotherapy ni kuua cancer cells, lakini healthy rapidly dividing cells pia zinaweza kuathiriwa. Katika male reproductive system, spermatogonia na spermatocytes hugawanyika na kudifferentiate mfululizo, hivyo ni sensitive kwa cytotoxic drugs.

Cyclophosphamide hubadilishwa mwilini kuwa active metabolites. Phosphoramide mustard iliyotumika katika cell experiments ni mojawapo. Maandishi yanaunganisha cyclophosphamide injury na:

• DNA interstrand crosslinks,
• cell-cycle disruption,
• germ-cell apoptosis,
• mitochondrial dysfunction,
• ATP production decrease,
• reactive oxygen species increase,
• disruption ya Sertoli–germ-cell microenvironment,
• hormonal dysregulation,
• decrease ya sperm density na motility.

Swali kuu la utafiti ni:

CP-1 polysaccharide fraction kutoka black-bean-processed Polygonati Rhizoma inaweza kuboresha cyclophosphamide-impaired spermatogenesis na sperm motility kupitia cellular na molecular mechanisms gani?

Asthenozoospermia ni nini?

Asthenozoospermia ni uwezo mdogo wa sperm kusonga kwa ufanisi kuelekea mbele. Sperm count inaweza kuwa normal, lakini kama sperm haziwezi kusonga kuelekea oocyte, fertilization probability inaweza kupungua.

Utafiti ulitumia progressive motility chini ya 32% kama criterion:

\[ \mathrm{PR\%} < 32\% \]

. PR inamaanisha progressive motility.

Total sperm motility na progressive motility si sawa. Sperm inayotetemeka mahali au kusonga kwa duara inaweza kuhesabiwa motile, lakini ili kufikia oocyte inahitaji kusonga mbele kwa mstari au arc pana.

CP-1 ni nini hasa?

CP-1 ni crude polysaccharide fraction kutoka black-bean-processed Polygonati Rhizoma, iliyoitwa “Crude Polysaccharide 1” katika utafiti.

Neno “crude polysaccharide” ni muhimu. CP-1 si pure drug yenye single fully defined molecular structure. Ni mixture ya components zenye molecular weights na pengine sugar chains tofauti.

CP-1 iliandaliwaje?

Hatua kuu zilizoripotiwa ni:

1. Black-bean-processed Polygonati Rhizoma ilikaushwa na kusagwa.
2. Raw material iliwekwa katika 95% ethanol kwa saa 48 katika 25 °C.
3. Baada ya ethanol kuondolewa, residue ililowekwa awali katika maji kwa saa moja.
4. Extraction ilifanywa kwa lita 25 za distilled water katika 100 °C kwa saa tatu.
5. Hot-water extraction ilirudiwa mara tatu.
6. Extracts ziliunganishwa na concentrated hadi one tenth ya initial volume.
7. Precipitation ilifanywa katika 40% ethanol kwa 24 hours katika 4 °C.
8. Precipitate ilikusanywa kwa centrifugation 15.000 g kwa dakika 10.
9. Product ilifreeze-dry na kisha dissolved tena katika maji.
10. Deproteinization kwa Sevag method ilifanywa angalau mara nne.

Molecular-weight distribution ya CP-1

Gel permeation chromatography ilionyesha main molecular-weight regions mbili.

Polydispersity index huhesabiwa:

\[ \mathrm{PDI} = \frac{M_w}{M_n} \]

Katika utafiti:

\[ \mathrm{PDI} = 27{,}18 \]

. Hii inaonyesha very broad molecular-weight distribution na kuthibitisha kwamba CP-1 si homogeneous pure polysaccharide.

Sugar na FT-IR characterization

Supplementary GC-MS chromatogram iliweka labels za maltose, arabinose, xylose, glucose na fructose peaks. Hata hivyo, detailed composition table ya molar ratios haikutolewa.

FT-IR spectrum iliripoti:

• O–H stretching karibu 3402 cm⁻¹,
• C–H stretching karibu 2949 cm⁻¹,
• bound-water au carbonyl-related band karibu 1639 cm⁻¹,
• C–H bending au carboxylate vibration karibu 1426 cm⁻¹,
• signals zinazohusiana na glycosidic bonds na pyranose rings katika 1048, 936 na 827 cm⁻¹.

Spectrum hii inaunga mkono carbohydrate-rich nature ya product, lakini haionyeshi ni specific polysaccharide chain gani inayosababisha biological activity.

Utata katika utambulisho wa chanzo cha mmea

Utangulizi unasema Polygonati Rhizoma ni rhizome ya Polygonatum sibiricum. Discussion inaandika kuwa CP-1 imetokana na Polygonatum cyrtonema polysaccharides.

Hizi ni species tofauti. Maandishi hayatoi botanical identity ya raw material kwa consistency. Katika natural-product studies, species, growing region, harvest time na processing method vinaweza kubadilisha chemical composition, hivyo tofauti hii ni muhimu.

Muundo wa animal experiment

Male C57BL/6J mice wenye wiki 8 na uzito wa 20 ± 2 g walitumika. Baada ya one-week acclimation, cyclophosphamide model ilitengenezwa.

Maandishi yanasema mice waliwekwa kwenye groups randomly, lakini randomization method haijaelezwa. Johnsen histology scoring ilisemwa kuwa blinded; haijaelezwa kama outcomes nyingine ziliassessiwa blinded.

Reproductive organ index

Testis, epididymis na seminal vesicle weights ziligawanywa kwa body weight:

\[ \mathrm{Organ\ indeksi} = \frac{\mathrm{organ\ ağırlığı}} {\mathrm{vücut\ ağırlığı}} \]

. Cyclophosphamide group ilionyesha decrease ya testis na accessory reproductive organ indices; CP-1 groups zilionyesha partial improvement. High-dose CP-1 kwa ujumla ilionyesha recovery kubwa kuliko low dose.

Sperm measurement ilifanywaje?

Epididymides zote mbili ziliwekwa katika 500 µL PBS yenye 10% FBS na kukatwa ili sperm ziachiliwe. Suspension iliwekwa 37 °C kwa dakika 30 na kuchunguzwa kwenye prewarmed counting chamber kwa computer-assisted sperm analysis.

Kila measurement ilirudiwa mara tatu kupunguza technical variability. Replicates hizi tatu si animals tatu tofauti; biological n ya kila group ni 5.

Kielelezo 1 kinaonyesha sperm outcomes vipi?

Bar charts za Figure 1 hazina exact numeric labels. Kwa kukadiria kutoka axes:

Thamani hizi zimesomwa kwa makadirio kutoka graph axes, si raw-data table. Exact individual values hazipo kwenye PDF.

Katika rapid progressive motility graph, low-dose CP-1 label imeandikwa “40 mg/kg”. Methods, other graphs na supplementary data zinasema low dose ni 20 mg/kg. Kwa hiyo 40 mg/kg katika Figure 1D inaonekana kuwa figure-label inconsistency; PDF pekee haiwezi kuthibitisha thamani sahihi.

Sperm morphology

Figure 1E inaonyesha sperm chache na low-motility appearance katika CTX group, na denser sperm fields katika CP-1 na sham groups.

Hata hivyo, hakuna quantitative morphology analysis ya head, midpiece au tail abnormalities kwa asilimia. Images ni representative micrographs.

Testis histology na Johnsen score

Sham group ina orderly seminiferous tubules, layered germ cells na mature sperm ndani ya lumen.

CTX group ina:

• disorganized seminiferous tubules,
• decreased tubule count/cell density,
• basal-layer damage,
• vacuoles,
• reduced sperm cells katika lumen.

CP-1-treated mice ziliripotiwa kuwa na germ-cell layers zilizopangwa zaidi, spermatocytes na spermatids nyingi zaidi na partial tubule recovery.

Johnsen score hupima completeness ya spermatogenesis katika seminiferous tubules kutoka 0–10. Angalau tubules 50 kwa testis zilipimwa randomly na blinded.

Graph inaonyesha takriban 9–10 katika sham, 5–6 katika CTX na 7–8 katika CP-1 groups. Hii inaonyesha damage reduction, lakini si complete return to sham.

Lengo la single-cell RNA sequencing

Whole-testis measurements huchanganya signals kutoka cell types tofauti. Single-cell RNA sequencing hupima expression ya kila cell ili kutambua:

• cell types zinazopungua/kuongezeka,
• genes zinazobadilika katika cell types maalum,
• developmental step gani ya spermatogenesis imezuiwa,
• cell-cell communication imebadilikaje.

ndilo lengo la uchambuzi huu.

Single-cell samples ziliandaliwaje?

Testes ziliwekwa katika preservation solution ndani ya dakika 30. Tissue ilikatwa na enzymatically digested kwa dakika 15 katika 37 °C.

Cell suspension ilipitia 40 µm filter, erythrocytes zikaondolewa, na cell density ikawekwa:

\[ 2 \times 10^5\ \mathrm{hücre/mL} \]

.

Cell capture/barcoding ilifanywa kwa Singleron Matrix na library prep kwa GEXSCOPE kit. Reads zilialigniwa kwa mouse reference genome GRCm38.

Quality-control criteria

Cells zifuatazo zilitolewa:

• chini ya genes 300,
• zaidi ya genes 4.500 kama possible doublets,
• zaidi ya UMI 75.000,
• mitochondrial gene proportion zaidi ya 50%.

Cells 78.277 kati ya 87.496 zilibaki.

Sehemu moja ya methods inaandika CeleScope version 2.0.7, nyingine 1.11.0. Software-version inconsistency hii inahitaji ufafanuzi kwa reproducibility.

UMAP cell map inaonyesha nini?

UMAP ni visualization method inayoweka cells zenye gene-expression profiles zinazofanana karibu kwenye 2D map. Points si anatomical positions; ni transcriptomic similarity.

Figure 2 inaonyesha cell types tisa kama clusters tofauti. Germ cells huunda broad developmental trajectory, huku Leydig, Sertoli, endothelial, fibroblast na immune cells zikiwa clusters tofauti.

Cell proportions zilibadilikaje?

Spermatogonia proportion haikubadilika sana. Mabadiliko makuu yalikuwa katika spermatocytes na spermatids.

• Sham: spermatids nyingi, spermatocytes chache zaidi.
• CTX: spermatid proportion ilipungua, spermatocyte proportion ikaongezeka.
• CP-1: spermatid proportion iliongezeka dhidi ya CTX.

Hii ilitafsiriwa kwamba cyclophosphamide inazuia spermatocyte-to-spermatid transition na CP-1 inaactivate tena kwa kiasi developmental step hii.

Cell count si sawa na animal count

Makumi ya maelfu ya cells hayamaanishi makumi ya maelfu ya independent biological samples. Cells kutoka mouse mmoja hushiriki biological history.

PDF haisemi wazi testes za mice wangapi zili-pooliwa kwa kila group, independent single-cell libraries ngapi zilitengenezwa au group-level biological replication ilifanyika vipi.

Kama cells zilihesabiwa kama independent observations, p-values zinaweza kuwa artificially small. Hii ni cellular pseudoreplication, limitation muhimu katika single-cell studies.

Pseudotime analysis inaonyesha nini?

Monocle2 iliweka cells kwenye developmental ordering kulingana na gene expression. Trajectory ni:

\[ \mathrm{SPG} \rightarrow \mathrm{SPC} \rightarrow \mathrm{SPD} \]

.

Ambapo:

• SPG: spermatogonium,
• SPC: spermatocyte,
• SPD: spermatid.

CTX group ilikuwa na fewer late-stage spermatids; CP-1 shifted distribution kiasi kuelekea healthy group.

Pseudotime si real-time tracking ya cell moja ikibadilika. Ni developmental ordering ya snapshot transcriptomes kutoka cells tofauti.

Pseudotime si jaribio la kufuatilia seli ileile kwa wakati halisi ikibadilika kutoka spermatogonium kuwa spermatid. Ni mpangilio wa maendeleo wa transcriptomes za papo hapo kutoka seli tofauti.

Genes zinazobadilika katika development

Pseudotime plots zilionyesha:

• Prm1, Prm2, Tnp1, Tnp2, Smcp, Oaz3 na Odf2 zikiongezeka kuelekea spermatid stage.
• Crisp2 ilikuwa prominent katika spermatocyte na spermatid stages.
• Catsperz, Catsper4, Dmrtb1 na Prdx6b zilihusishwa zaidi na spermatocyte stage.

Mitochondrial/energy genes kama Ndufb5, Ndufc1 na Atp6v1g1 pia zilibadilika. Hii inaonyesha kwamba sperm development inahitaji major cellular reprogramming ya structure na energy production.

Differential gene analysis

Gene-selection criteria zilikuwa:

\[ \mathrm{Düzeltilmiş}\ p < 0{,}05 \]

\[ |\log_2(\mathrm{kat\ değişimi})| > 0{,}15 \]

.

Spermatocytes zilikuwa germ-cell group yenye genes nyingi zaidi zilizobadilika.

Venn diagram ilionyesha genes 47 za pamoja. Lakini figure legend, comparison labels na main text kuhusu “genes zilizoshuka kwa CTX na kupanda kwa CP-1” hazioani kikamilifu.Legend ina baadhi ya sets kama “up in CTX vs sham” na “up in CTX vs CP-1”, lakini text inasema genes kama Crisp2 hupungua CTX na kupanda CP-1. Kwa hiyo direction ya 47-gene intersection haiwezi kureconstructed kwa uhakika kutoka labels pekee.

qPCR, ELISA na Western blot kwa Crisp2 zinaunga mkono direction ya text: decrease baada ya CTX/PM na increase baada ya CP-1.

CRISP2 ni nini na kwa nini ni muhimu?

CRISP2 ni member ya cysteine-rich secretory protein family inayopatikana kwenye sperm. Utafiti uliripoti high expression katika spermatocytes na spermatids.

CRISP2 inahusishwa na:

• sperm flagellar movement,
• acrosome reaction,
• sperm–oocyte interaction,
• CatSper calcium-channel complex.

UMAP expression map inaonyesha Crisp2 signal nyingi katika spermatocyte na spermatid regions.

Uhusiano unaowezekana na CatSper channel

CatSper ni ion-channel complex katika sperm tail inayodhibiti calcium entry. Calcium changes zinaweza kubadilisha flagellar beating na powerful progressive movement.

Katika utafiti, Catsperz na Catsper4 zilipungua baada ya CTX/PM na kuongezeka baada ya CP-1.

Uhusiano unaopendekezwa ni:

\[ \mathrm{CRISP2/CatSper\ işlevi} \rightarrow \mathrm{Ca^{2+}\ düzenlenmesi} \rightarrow \mathrm{kamçı\ hareketi} \rightarrow \mathrm{sperm\ hareketliliği} \]

. Lakini intracellular sperm calcium flux au CatSper current haikupimwa. Hivyo calcium mechanism inapendekezwa kutokana na gene expression na previous biology.

miR-27b inaweza kufanyaje kazi?

MicroRNAs ni small RNAs zinazoweza kupunguza protein production kwa kufunga target mRNAs. Utafiti unadhania miR-27b negatively regulates CRISP2.

Mouse testis ilionyesha:

• CTX → miR-27b increase
• CTX → Crisp2 decrease
• CTX + CP-1 → miR-27b decrease
• CTX + CP-1 → Crisp2 increase

.

Serum CRISP2 protein pia ilipungua CTX na kuongezeka CP-1. Hata hivyo, haijathibitishwa jinsi serum CRISP2 inavyowakilisha functional testicular CRISP2.

Cell-culture experiments

GC-2spd(ts) mouse spermatocyte cells zilitumika. Phosphoramide mustard ilijaribiwa katika 25–200 µg/mL.

100 µg/mL PM iliripotiwa kupunguza cell viability kwa takriban 50%. CP-1 ilijaribiwa 5–135 µg/mL; 100 µg/mL CP-1 ikachaguliwa kwa intervention dhidi ya PM injury.

Supplementary text sehemu moja inasema optical density huongezeka kadiri CP-1 concentration inavyoongezeka, kisha inasema higher concentration hupunguza optical density. Graph inaonyesha CP-1 alone rising katika range, lakini PM + CP-1 best recovery karibu 100 µg/mL. Maelezo haya hayaoani kabisa.

miR-27b mimic/inhibitor experiment

Cells ziligawanywa kwenye groups nne:

• Negative control
• 37,5 nM miR-27b mimic
• 37,5 nM miR-27b mimic + inhibitor
• miR-27b mimic + 100 µg/mL CP-1

. miR-27b mimic ilipunguza CRISP2 mRNA/protein. Inhibitor ilirejesha CRISP2 kiasi. CP-1 pia iliongeza CRISP2 hata mimic ikiwa ipo.

Hii inaonyesha CP-1 inaweza kupinga suppressive effect ya miR-27b. Lakini haijulikani ikiwa CP-1 inaathiri:

• miR-27b transcription,
• miRNA maturation,
• mRNA binding,
• au CRISP2 protein stability.

haijabainishwa ni katika hatua gani hasa athari hiyo hutokea.

Oxidative-stress findings

ROS-related gene-set activity iliongezeka hasa katika spermatogonia, spermatocytes na Leydig cells baada ya cyclophosphamide.

Malondialdehyde ni product ya lipid oxidative damage; SOD ni antioxidant enzyme inayodetoxify superoxide radicals.

Pattern ilikuwa:

\[ \mathrm{CTX} \rightarrow \mathrm{MDA}\uparrow + \mathrm{SOD}\downarrow \]

\[ \mathrm{CP\!-\!1} \rightarrow \mathrm{MDA}\downarrow + \mathrm{SOD}\uparrow \]

. High-dose CP-1 ilionekana stronger kuliko low dose; positive control ilikuwa na highest SOD recovery.

Prdx6b ni antioxidant enzyme gene inayohusika na detoxification ya hydrogen peroxide na organic hydroperoxides. PM + CP-1 group ilikuwa na Prdx6b expression juu kuliko PM alone.

Inflammation findings

Katika PM-injured GC-2spd(ts) cells:

• TNF-α,
• IL-1β,
• IL-6

ziliongezeka.

100 µg/mL CP-1 ilipunguza cytokines zote tatu. Hii ni cell-culture result; haionyeshi systemic inflammation imepungua katika mice au humans.

Hormone results

Cyclophosphamide group ilionyesha:

• Testosterone decrease,
• Inhibin B decrease,
• FSH increase,
• LH increase.

CP-1 ilireverse mabadiliko haya kiasi kwa dose-related manner.

High FSH na LH zinaweza kuonekana wakati central endocrine system inaongeza stimulation kwa testis yenye function iliyopungua. Inhibin B ilitumika kama marker inayohusiana na spermatogenesis capacity.

Hormones zilipimwa serum; direct cellular mechanism ya hormone synthesis katika pituitary, Sertoli au Leydig cells haikuchunguzwa. Hivyo haiwezi kusemwa kwa uhakika kutoka serum alone kwamba “CP-1 directly increases hormone secretion”.

Cell–cell communication

CellChat ilitabiri ligand–receptor communication kati ya germ cells na supporting somatic cells.

Sham group ilikuwa na dense connections kati ya spermatogonia/spermatocytes/spermatids na Sertoli, Leydig, endothelial na macrophage cells.

Baada ya CTX, predicted communication ya Sertoli cells hasa ilipungua sana; baada ya CP-1 sehemu ya connections ilirudi.

Hata hivyo, supplementary graph haionyeshi universal one-direction decrease katika cell groups zote. Baadhi ya spermatocyte/spermatid connection counts zinaonekana juu zaidi CTX kuliko sham. Tafsiri salama ni kwamba cyclophosphamide hubadilisha cell-communication network kwa ujumla na kuvuruga hasa Sertoli-centered support network.

CellChat results ni predictions. Hazipimi actual protein secretion au physical contact; zinakokotoa possible ligand–receptor links kutoka gene expression.

Liver na safety evaluation

Supplementary data zilisema ALT na AST hazikutofautiana significantly. Waandishi walitafsiri hii kama ushahidi kwamba dose ya CP-1 ilikuwa “within a safe range”.

Hata hivyo, ALT/AST pekee:

• hutoa limited short-term liver information,
• hazitathmini kidney function,
• hazionyeshi long-term toxicity,
• haziondoi organ histological damage,
• hazithibitishi genetic safety ya germ cells.

Figure legend inasema “liver and kidney function”, lakini measures zilikuwa ALT na AST tu. Creatinine, BUN au kidney histology hazijaripotiwa.

Je, CP-1 effect ni pathway moja tu?

Results zinaonyesha broader pattern:

Nguvu za utafiti

• Multiple experimental levels: Mouse, histology, cell culture, single-cell transcriptomics, qPCR, ELISA na Western blot.
• CP-1 doses mbili: 20 na 100 mg/kg ziliruhusu dose-related pattern.
• Positive control: Clomiphene citrate group.
• CASA sperm measurements. Concentration na motility zilitathminiwa kwa computer-assisted system.
• Blinded histology scoring: Angalau tubules 50 kwa Johnsen.
• 78.277-cell testis map. Mabadiliko yalitenganishwa katika kiwango cha cell type.
• Developmental trajectory analysis. Uharibifu katika spermatocyte–spermatid transition ulionyeshwa.
• miRNA intervention: Mimic/inhibitor experiments.
• Protein-level validation: Western blot na serum ELISA ya CRISP2.
• Partial chemical characterization ya CP-1: Molecular-weight distribution, GC-MS, FT-IR.
• Oxidative stress, inflammation na hormones zimetathminiwa pamoja.

Mapungufu ya utafiti

• Hakuna peer review: Preprint.
• Author information haipo kwenye PDF. Scientific responsibility na institution information haziwezi kuthibitishwa kutoka kwenye maandishi yaliyopakiwa.
• Animals wachache sana: Five per group.
• Hakuna sample-size calculation. Haijaelezwa kwa nini wanyama watano walichukuliwa kuwa wa kutosha.
• Randomization details hazipo. Njia ya group allocation haijaelezwa.
• Blinding ni limited: Johnsen scoring tu ndiyo imeandikwa wazi.
• Hakuna human data. Hakuna human semen sample, patient group au clinical treatment.
• Real fertility haijapimwa: Mating, pregnancy, live birth, offspring health.
• CP-1 si pure molecule: PDI 27,18 heterogeneous mixture.
• Active component haijulikani. Haijaonyeshwa ni polysaccharide chain gani inayosababisha athari.
• Plant species name inconsistent: Maandishi yanatumia zote Polygonatum sibiricum na Polygonatum cyrtonema.
• Sugar composition si fully quantitative. Molar ratios za monosaccharides hazijatolewa.
• Low-dose label inconsistent: 40 mg/kg katika Figure 1D, 20 mg/kg kwingine.
• Single-cell biological replication haijaelezwa. Haijulikani independent libraries ngapi zilitengenezwa kutoka mice wangapi.
• Cellular pseudoreplication risk. Makumi ya maelfu ya cells yanaweza kuwa yamefasiriwa kama independent animals.
• CeleScope versions mbili tofauti. CeleScope imetajwa kwa versions mbili tofauti.
• DEG direction unclear. Gene directions katika Venn legend hazioani na main text.
• Multiple-testing details limited. Baadhi ya analyses zinataja correction, lakini method ya correction kwa cellular comparisons zote haijaelezwa.
• Exact effect sizes nyingi hazipo. Many results zimeonyeshwa katika bar graphs bila exact values.
• Raw individual-animal table haipo. Individual-animal results na confidence intervals hazijaonyeshwa.
• Hakuna direct miRNA target luciferase test. Hakuna new luciferase reporter assay.
• CatSper function haijapimwa directly. Calcium current au channel electrophysiology haikufanywa.
• Sperm DNA integrity haijapimwa. Haijulikani kama genetic damage ilirekebishwa hata motility ilipoongezeka.
• Sperm morphology si quantitative. Representative images zilitolewa lakini anomaly percentage haikuhesabiwa.
• Long-term safety haipo. Ni treatment ya siku 30 tu.
• Safety markers hazitoshi: ALT na AST pekee zilitumiwa kama general safety evidence.
• Kidney safety haijapimwa licha ya figure label. Figure title inataja kidney function lakini renal biochemistry haikutolewa.
• Clinical relevance ya PM/CP-1 cell doses haijulikani. Clinical equivalent ya PM na CP-1 cell doses haijulikani.
• Cell-viability supplementary text inajikanganya. Cell-viability supplementary text ina contradiction ya ndani.
• Data accession number ya single-cell haijaripotiwa. Open repository accession ya single-cell sequencing data haipo kwenye PDF.

Utafiti unasema nini?

• Cyclophosphamide ilipunguza sperm count na motility kwa mice.
• CP-1 ilirekebisha kiasi.
• 100 mg/kg ilionekana stronger kuliko 20 mg/kg katika measures nyingi.
• CP-1 iliboresha testis histology na Johnsen score.
• Cyclophosphamide ilivuruga spermatocyte-to-spermatid transition.
• CP-1 ilirejesha spermatid population kiasi.
• CP-1 iliongeza sperm-motility na spermatogenesis gene programs.
• CTX/PM ziliinua miR-27b na kupunguza CRISP2.
• CP-1 ilipunguza miR-27b na kuongeza CRISP2.
• miR-27b mimic ilipunguza CRISP2; inhibitor/CP-1 zilipunguza suppression.
• CP-1 ilipunguza oxidative-stress na inflammatory markers.
• CP-1 iliboresha serum-hormone disturbance kiasi.
• CP-1 ilirejesha baadhi ya cell-communication networks.

Utafiti haussemi nini?

• Hauonyeshi CP-1 inatibu asthenozoospermia kwa binadamu.
• Hauonyeshi inalinda fertility kwa chemotherapy patients.
• Hauonyeshi pregnancy/live-birth rate inaongezeka.
• Hauthibitishi inazuia sperm DNA damage.
• Hauonyeshi ni safe wakati wa cancer treatment.
• Hauonyeshi haibadilishi antitumor effect ya cyclophosphamide.
• Hauonyeshi hakuna drug interaction na chemotherapy.
• Haupeani safe/effective human dose.
• Hauonyeshi mouse doses 20/100 mg/kg zinaweza kubadilishwa moja kwa moja kuwa human doses.
• Hauthibitishi effect yote inategemea miR-27b/CRISP2 pekee.
• Hautambui molecule gani ndani ya CP-1 ndiyo active.
• Hauonyeshi kula Polygonati Rhizoma au black beans kunaleta matokeo sawa.
• Hauonyeshi herbal supplements zinazuia chemotherapy-related infertility.

Umuhimu kwa historia

Chemotherapy-related male reproductive injury imechunguzwa muda mrefu kupitia oxidative stress, DNA damage na hormone disturbance. Utafiti huu unaongeza cell-type-level view ili kuonyesha spermatogenesis step gani inaathirika zaidi.

Single-cell data zinaonyesha si “general gene decrease” tu; spermatocyte–spermatid transition, Sertoli-support network na sperm-motility genes zinaweza kuharibika tofauti.

Umuhimu kwa sasa

Mchango mkuu ni kutazama chemotherapy-related motility loss katika levels nne zinazohusiana:

1. Structural testis injury
2. Developmental distribution ya germ cells
3. miR-27b/CRISP2/CatSper-related molecular program
4. Oxidative, inflammatory na hormonal microenvironment

Hii inaonyesha sperm count pekee haitoshi; developmental stage, energy metabolism, calcium signaling na supporting cells zinahitaji kuangaliwa pamoja.

Umuhimu kwa siku zijazo

Hatua zinazohitajika ni:

• larger independent animal groups,
• independent single-cell libraries per mouse,
• separate biological replication ya testes,
• fractionation ya CP-1,
• identification ya active polysaccharide structure,
• botanical chemical/genetic verification,
• direct miR-27b–Crisp2 reporter assay,
• sperm calcium flux na CatSper channel measurements,
• sperm DNA fragmentation/chromatin integrity,
• mating/pregnancy/live-birth studies,
• offspring developmental/genetic safety,
• testing whether CP-1 alters cyclophosphamide antitumor effect,
• pharmacokinetic/tissue-distribution studies,
• long-term liver/kidney/immune safety,
• human testis organoid au human sperm validation,
• controlled clinical trials only after adequate preclinical validation.

Maana kwa wagonjwa na maisha ya kila siku

Kwa wanaume wanaotarajiwa kupata chemotherapy, reproductive health ni quality-of-life issue muhimu. Lakini utafiti huu hauungi mkono self-use ya CP-1, Polygonati Rhizoma au herbal products zinazofanana.

Herbal/polysaccharide products zinaweza:

• kubadilisha absorption/metabolism ya chemotherapy drugs,
• kuingiliana na liver enzymes,
• kuathiri immune system,
• kuwa na purity/dose variability,
• kinadharia kubadilisha cancer-treatment efficacy.

Utafiti haukuchunguza kama CP-1 huhifadhi tumor-killing effect ya cyclophosphamide.

Kwa wagonjwa wanaotaka fertility preservation kabla ya chemotherapy, utafiti huu si clinical treatment recommendation; ni experimental research direction ya protective mechanisms zinazoweza kuendelezwa baadaye.

Mbinu na Matokeo ya Utafiti

Muhtasari wa kiufundi wa muundo wa utafiti

Single-cell data distribution

Modeli kuu ya molekuli

Maana ya kiufundi ya Kielelezo 2

Figure 2 inaunda single-cell transcriptomic map ya testis. UMAP clusters zinatenganisha cell types tisa, dot plot inaonyesha marker genes, na heatmap inaonyesha cell-type-specific expression signatures.

Main message ya proportion plot ni spermatid population kupungua baada ya CTX na kurudi kiasi kwa CP-1.

Maana ya kiufundi ya Kielelezo 3

Figure 3 inajumuisha:

• differential genes,
• GO enrichment,
• sperm-motility gene-set scores,
• miR-27b na Crisp2 qPCR,
• serum CRISP2 ELISA,
• miRNA mimic/inhibitor experiments,
• CRISP2 Western blot.

Hii ndiyo sehemu yenye nguvu zaidi kwa miR-27b/CRISP2 claim, lakini Venn comparison directions zina ambiguity.

Kielelezo hiki ndicho sehemu yenye nguvu zaidi ya majaribio inayounga mkono dai la miR-27b/CRISP2 katika utafiti. Hata hivyo, kuna tatizo la uwazi kati ya mielekeo ya ulinganisho katika mchoro wa Venn na maelezo katika maandishi makuu.

Maana ya kiufundi ya Kielelezo 4

Figure 4 inaonyesha developmental trajectory kutoka spermatogonia hadi spermatids na stage-specific gene rise.

Late-stage cells zilipungua CTX na partial recovery ikaonekana CP-1. Crisp2 ilikuwa katika spermatocyte/spermatid; protamine na late spermiogenesis genes ziliongezeka zaidi katika spermatid stage.

Maana ya kiufundi ya Kielelezo 5

Figure 5 inaonyesha CP-1 effects kwenye oxidative stress na inflammation:

• ROS gene-set activity decrease,
• MDA decrease,
• SOD increase,
• Prdx6b increase,
• TNF-α, IL-1β na IL-6 decrease.

Baadhi ya animal biochemistry results ni n = 5, na baadhi ya molecular/cell-culture results ni n = 3.

Maana ya kiufundi ya Kielelezo 6

Figure 6 inaonyesha serum testosterone, inhibin B, FSH na LH.

Low testosterone/inhibin B na high FSH/LH pattern baada ya CTX iliboreka kiasi kwa CP-1. High dose ilikuwa stronger kwenye measures nyingi.

Tofauti muhimu ya kiufundi kuhusu CP-1

Utafiti unaonyesha biological improvement kwa CP-1, lakini CP-1 si single defined molecule.

Current experiments zinaonyesha:

\[ \mathrm{CP\!-\!1\ karışımı} \rightarrow \mathrm{biyolojik\ sonuç} \]

lakini hazionyeshi bado:

\[ \mathrm{belirli\ saf\ polisakkarit\ yapısı} \rightarrow \mathrm{miR\!-\!27b} \rightarrow \mathrm{CRISP2} \]

. Haijulikani component gani inaingia cells, inabadilishaje miR-27b, au oral dosing huleta species gani kwenye blood/testis.

Haijulikani ni kijenzi gani cha CP-1 kinachofika kwenye seli, jinsi kinavyobadilisha miR-27b, na kwa namna gani baada ya kutolewa kwa njia ya mdomo kinafika kwenye damu au testis.

Matokeo muhimu zaidi ya kiufundi

Matokeo muhimu zaidi ni kwamba cyclophosphamide-related sperm motility loss haionekani kama sperm-count problem pekee, bali kama spermatocyte–spermatid developmental block na miR-27b/CRISP2-related gene-regulation problem.

Katika CP-1-treated mice:

• spermatid formation iliongezeka,
• CRISP2 ilirecover,
• CatSper-related genes ziliongezeka,
• oxidative/inflammatory stress ilipungua,
• hormone pattern iliboreka kiasi,
• sperm motility iliongezeka.

Hii ni promising preclinical mechanism lakini haiwezi kufasiriwa kama clinical treatment result kutokana na small groups, heterogeneous CP-1 na kukosekana kwa human data.

Maelezo ya Chanzo na Mbinu

Maudhui haya yanategemea utafiti wenye kichwa “Black-bean-processed Polygonati Rhizoma Crude Polysaccharide 1 (CP-1) alleviates cyclophosphamide-induced asthenozoospermia via the miR-27b/CRISP2-associated sperm motility”.

Majina ya waandishi, taasisi na corresponding-author contact hayapo kwenye PDF iliyopakiwa. Kwa hiyo author list haijathibitishwa kutoka PDF na hakuna majina ya nje yaliyoongezwa.

Utafiti ni preclinical animal and in vitro study unaochanganya cyclophosphamide-induced asthenozoospermia model katika male C57BL/6J mice, GC-2spd(ts) mouse spermatocytes, single-cell RNA sequencing, histology, sperm analysis, hormone measurements na miRNA interventions.

Si human clinical study. Hakuna human semen sample, infertility patient group, pregnancy outcome au live-birth data.

Maandishi yana “This preprint research paper has not been peer reviewed” na “Preprint not peer reviewed”. Kwa hiyo utafiti haujapitia peer review. Journal acceptance, DOI au final peer-reviewed publication havijathibitishwa.

Animal experiments ziliripotiwa kuidhinishwa na Shenzhen Huateng Biopharmaceutical Technology Co., Ltd. kwa namba B202501-3.

Utafiti uliripotiwa kufadhiliwa na Guangdong Province Guangdong–Shenzhen Joint Key Project, Shenzhen Medical Research Fund, National Natural Science Foundation of China, Shenzhen Science and Technology Program na Guangdong Basic and Applied Basic Research Foundation. Hakuna conflict of interest iliyoripotiwa.

CP-1 si single-structure pure drug. Ni crude heterogeneous polysaccharide mixture yenye broad molecular-weight distribution. Plant source imeandikwa tofauti kama Polygonatum sibiricum na Polygonatum cyrtonema.

Independent animal na library counts per group kwa single-cell experiments hazijaelezwa. Kwa hiyo haiwezekani kujua kwa usahihi cellular statistics zinawakilisha independent biological replicates kwa kiwango gani.

Figure 1D ina 40 mg/kg kama low dose, wakati methods na other graphs zinasema 20 mg/kg. Venn differential-gene directions pia hazioani kikamilifu na main text.

ALT/AST similarity ni limited short-term liver signal tu. Utafiti hautoi general safety, kidney safety, long-term toxicity, sperm DNA safety au chemotherapy drug-interaction guarantee.

Utafiti haupendekezi CP-1, Polygonati Rhizoma products au similar supplements kwa humans receiving chemotherapy. Athari kwa cyclophosphamide antitumor activity haijachunguzwa.

Makala hii imeandaliwa tu kutokana na methods, graphs, histology images, single-cell analyses, supplementary data na author interpretations katika PDF iliyopakiwa. Hakuna human efficacy, clinical treatment, fertility guarantee, safe dose au product recommendation iliyoongezwa bila kuwa kwenye PDF.